Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Trevi Therapeutics Inc (NASDAQ: TRVI) was $2.58 for the day, down -3.73% from the previous closing price of $2.68. In other words, the price has decreased by -$3.73 from its previous closing price. On the day, 64317.0 shares were traded. TRVI stock price reached its highest trading level at $2.7 during the session, while it also had its lowest trading level at $2.57.
Ratios:
Our analysis of TRVI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.55. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 13, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On April 12, 2023, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $6.
On November 22, 2022, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $6.SVB Leerink initiated its Outperform rating on November 22, 2022, with a $6 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 29 ’24 when SCIASCIA THOMAS sold 53,368 shares for $2.55 per share. The transaction valued at 136,110 led to the insider holds 214,433 shares of the business.
Delfini Lisa sold 4,350 shares of TRVI for $11,485 on May 22 ’24. The Chief Financial Officer now owns 53,279 shares after completing the transaction at $2.64 per share. On May 20 ’24, another insider, GOOD JENNIFER L, who serves as the President & CEO of the company, sold 25,037 shares for $2.86 each. As a result, the insider received 71,576 and left with 213,313 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 188061728 and an Enterprise Value of 116512696.
Stock Price History:
The Beta on a monthly basis for TRVI is 1.01, which has changed by 0.17621148 over the last 52 weeks, in comparison to a change of 0.25510752 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $4.00, while it has fallen to a 52-week low of $0.97. The 50-Day Moving Average of the stock is -5.45%, while the 200-Day Moving Average is calculated to be 18.31%.
Shares Statistics:
TRVI traded an average of 224.38K shares per day over the past three months and 425360 shares per day over the past ten days. A total of 68.28M shares are outstanding, with a floating share count of 46.01M. Insiders hold about 34.68% of the company’s shares, while institutions hold 39.86% stake in the company. Shares short for TRVI as of 1718323200 were 960966 with a Short Ratio of 4.28, compared to 1715731200 on 986351. Therefore, it implies a Short% of Shares Outstanding of 960966 and a Short% of Float of 2.23.
